Congress Materials – European Chron's and Colitis Organization (ECCO 2026)
2026 European Crohn's & Colitis Organization Congress | Feb 18-20 | Stockholm, Sweden
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Assessment of IBD-Specific Quality of Life (IMPACT-III) Symptoms After Treatment With Ustekinumab in Paediatric Crohn’s Disease
Anne M. Griffiths, Robert Fieo, Sheri Volger, Richard Strauss, Lilianne Kim
Association of Endoscopic, Histologic, and Composite Outcomes with Long-Term Guselkumab Efficacy in Ulcerative Colitis: 2-year Results From the QUASAR Long-Term Extension
Fernando Magro, David T. Rubin, Gary R. Lichtenstein, Yelina Alvarez, Thomas Baker, Ye Miao, Laurent Peyrin-Biroulet
Clinical Characteristics and Treatment Patterns of Ustekinumab in Patients with Crohn’s Disease: Sub-Group Analysis From a one-Year Prospective Nationwide K-STAR Study in Korea
Tae Oh Kim, Ki-Hwan Song, Ok-Jae Lee, Dongwoo Kim, Hyun Seok Lee, Yun Jin Chung, Dong Il Park, Ki Bae Bang, Hee Seok Moon, Seong-Eun Kim, Jihye Park, Ben Kang, Hyun Joo Jang, Seong Ran Jeon, Youngdoe Kim, Jong Min Choi, YoungJa Lee, Byung Ik Jang
Computer Vision Endoscopy Scoring for Ulcerative Colitis Disease Severity (ARGES-CMES): A Comparison Between Adult and Paediatric Clinical Trials
Natalia Alves, Krishna Chaitanya, Pooya Mobadersany, Chaitanya Parmar, Anne Griffiths, Richard K. Russell, Dan Turner, Jeffrey Hyams, Louis Ghanem, Camilla Richmond, Els Van Limbergen, Paul Ufberg, Richard Strauss, Nicholas Skomrock, Gabriela Oana Cula, Kristopher Standish, Pablo F. Damasceno
Dose Escalation in Participants with Primary/Secondary Loss of Response to Conventional Dosing of Ustekinumab in Paediatric Crohn’s Disease (UNITI Jr Study)
Richard K. Russell, Elisabeth De Greef, Dan Turner, Jeffrey S. Hyams, Anne M. Griffiths, Stanley A. Cohen, Joel R. Rosh, Jarosław Kierkuś, Bartosz Korczowski, Monika Meglicka, Edaire Cheng, Richard Strauss, Els Van Limbergen, Laurie S. Conklin, Omoniyi J. Adedokun, Lilianne Kim, Sheri Volger
Efficacy and Safety of Guselkumab for Ulcerative Colitis Through Week 140 of the QUASAR Long-Term Extension Study
Laurent Peyrin-Biroulet, Brian Bressler, Axel Dignass, Tadakazu Hisamatsu, Bruce E. Sands, Yelina Alvarez, Thomas Baker, Nicole Shipitofsky, Ye Miao, Hongyan Zhang, Gary R. Lichtenstein, David T. Rubin, Jessica R. Allegretti
Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn’s Disease Who Had Maintenance Dose Adjustment: Results From the Phase 3 GALAXI 2 & 3 Long-Term Extension
Remo Panaccione, Tadakazu Hisamatsu, Anita Afzali, Rian Van Rampelbergh, Jacqueline Yee, Wilbert van Duijnhoven, Christopher Corbett, Bruce E. Sands, Silvio Danese
Efficacy and Safety of Guselkumab Through Week 96 After Intravenous or Subcutaneous Induction in Participants With Crohn’s Disease: Phase 3 Long-term Extension Data From GALAXI 2, GALAXI 3, and GRAVITI
Geert R. D’Haens, David T. Rubin, Anita Afzali, Ailsa Hart, Tadakazu Hisamatsu, Nat A. Terry, Mobolaji Olurinde, Rian Van Rampelbergh, Jacqueline Yee, Wilbert van Duijnhoven, Chris Corbett, Elizabeth Merrall, Qian Cao, Remo Panaccione, Julián Panés, Flavio Steinwurz, Silvio Danese, Bruce E. Sands
Efficacy of Intravenous and Subcutaneous Guselkumab Induction By Weight and Body Mass Index in Patients with Crohn’s Disease: Results From the Phase 3 GALAXI and GRAVITI Studies
Parakkal Deepak, Andres J. Yarur, Tadakazu Hisamatsu, Rian Van Rampelbergh, Wilbert van Duijnhoven, Shashi Adsul, Darren Piscitelli, David T. Rubin, Silvio Danese
Efficacy of subcutaneous guselkumab in moderately to severely active ulcerative colitis by induction week 12 clinical response status: Week 48 results from the phase 3 ASTRO study
Silvio Danese, Millie Long, Laurent Peyrin-Biroulet, Tadakazu Hisamatsu, Thomas Baker, Mary Kavalam, Yelina Alvarez, Lingjing Jiang, Hongyan Zhang, David T. Rubin, Jessica Allegretti
Endoscopic and Histologic Results From the UNITI Jr Study of Ustekinumab in Paediatric Crohn’s Disease
Elisabeth De Greef, Dan Turner, Jarosław Kierkuś, Bartosz Korczowski, Monika Meglicka, Richard K. Russell, Stanley A. Cohen, Jeffrey S. Hyams, Anne M. Griffiths, Joel R. Rosh, Richard Strauss, Els Van Limbergen, Omoniyi J. Adedokun, Lilianne Kim, Patrick Branigan, Sheri Volger, Edaire Cheng
Evaluation of Complete Bowel Symptomatic Remission (CBSR) in Patients With Moderately to Severely Active Ulcerative Colitis
Peter D.R. Higgins, Yelina Alvarez, Thomas Baker, Matthew Germinaro, Robert Fieo, Kelly Kato, Chenglong Han
Exposure Optimisation Substudy (EOS) of Ustekinumab in Paediatric Ulcerative Colitis (US): Q4W Results From the Phase 3 UNIFI Jr Study
Elisabeth De Greef, Richard K. Russell, Dan Turner, Anne M. Griffiths, Jeffrey S. Hyams, Stanley A. Cohen, Joel R. Rosh, Jarosław Kierkuś, Bartosz Korczowski, Monika Meglicka, Richard Strauss, Els Van Limbergen, Laurie S. Conklin, Omoniyi J. Adedokun, Jose Salas, Yuhua Wang, Paul J. Ufberg
Extraintestinal Manifestations in Participants with Moderately to Severely Active Crohn’s Disease: Results From the Phase 3 GALAXI 2 & 3 Studies
Silvio Danese, Tadakazu Hisamatsu, Rian Van Rampelbergh, Wilbert van Duijnhoven, Gustavo Scapini, Shashi Adsul, David T. Rubin
IBD-GAPS: Inflammatory Bowel Disease Guidelines Alignment in Clinical Practice Survey
Christian Selinger, Klaartje Bel Kok, Hannah Gordon, Kamal Patel, Jenny Quinn, Chinmay Munje, Barbara Beiderbeck, Seth Francis-Graham, Eve Sullivan, Madeleine Smith, Louisa Burton, Gordon Moran
Icotrokinra, the First Targeted Oral Peptide That Selectively Blocks the Interleukin-23 Receptor, Reduces Systemic and Tissue Inflammatory Burden in Ulcerative Colitis: Results From the ANTHEM-UC Study
Edouard Louis, Vipul Jairath, Britta Siegmund, Arun Kannan, Martha Zeeman, Amy Hart, David Strawn, Swati Venkat, Lynn Tomsho, Bradford McRae, Darren Ruane, Lindsey Surace, Ngozi Erondu, Jia Zhan, Minhu Chen, Karen Chachu, Katsuyoshi Matsuoka, Jimmy Limdi, Grazyna Rydzewska, Maria T. Abreu, Edward V. Loftus Jr.
Impact of Disease Duration on Clinical and Endoscopic Responses at 1 Year in Patients with Crohn’s Disease Treated with Guselkumab: Pooled Analysis of the GALAXI 2 & 3 Studies
Marc Ferrante, Mathurin Fumery, Raja Atreya, Rian Van Rampelbergh, Wilhelmus van Duijnhoven, Ivana Bravatà, Maciej Nazar, Jacqueline van Denderen, Victoria McCaffrey, Alessandro Armuzzi
Intravenous and Subcutaneous Guselkumab Induction Are Both Efficacious in Patients with Ulcerative Colitis Across Weight Quartile and BMI Subgroups: Week 12 Results From the Phase 3 QUASAR and ASTRO Studies
Andres J. Yarur, Parakkal Deepak, Tadakazu Hisamatsu, Yelina Alvarez, Thomas Baker, Shashi Adsul, Darren Piscitelli, Ye Miao, David T. Rubin, Axel Dignass
PCDAI Eligibility Criteria Into Clinical Trials: Post Hoc Analysis of the UNITI Jr Study of Ustekinumab in Paediatric Crohn's Disease: Improving Alignment Between Paediatric and Adult Clinical Trial Inclusion Criteria
Richard K. Russell, Sheri Volger, Ann M. Griffiths, Jeffrey S. Hyams, Elisabeth De Greef, Rob Fieo, Richard Strauss, Lilianne Kim, Auguste Gaddah, Amy Hemperly
Pharmacokinetics and Exposure-Response Relationships of Guselkumab Intravenous or Subcutaneous Induction in Participants with Ulcerative Colitis
Laurent Peyrin-Biroulet, Zhenhua Xu, Jie Shao, Tadakazu Hisamatsu, Millie Long, Silvio Danese, Matthew Germinaro, Marion L. Vetter, Shadi Yarandi, Thomas Baker, Jessica R. Allegretti, David T. Rubin
Predictors of Endoscopic Remission at 1 Year in Patients with Ulcerative Colitis Treated with Guselkumab: Post-Hoc Analyses of the QUASAR Trial
David T. Rubin, Mathurin Fumery, Alessabdri Armuzzi, Marc Ferrante, Thomas Baker, Yelina Alvarez, Ivana Bravatà, Maciej Nazar, Jacqueline van Denderen, Victoria McCaffrey, Raja Atreya
Pregnancy Outcomes in Maternal Exposure to Guselkumab: Review of Cases Reported to the Company's Global Safety Database
Uma Mahadevan, Millie Long, Mette Julsgaard, Connie Lin, Anja Geldhof, Mauricio Rosas Ballina, Hewei Li, Javier P. Gisbert, María Chaparro
Real World Evidence of Ustekinumab on Health-Related Quality of Life in Patients with Crohn’s Disease: A Prospective Nationwide K-STAR Study in Korea
Sung Noh Hong, Su Bum Park, Dong Hyun Lee, Hong Sub Lee, Jin Soo Moon, Bong Min Ko, Young-Seok Cho, Soo-Jung Park, Chang Seok Bang, Sang-Bum Kang, Chang Beom Ryu, Dae Hyeon Cho, Hyun Jin Kim, Ho Suk Kang, Youngdoe Kim, Jong Min Choi, YoungJa Lee, Jong Pil Im
Safety and Efficacy of Ustekinumab in Paediatric Ulcerative Colitis (UC): Results From the Phase 3 UNIFI Jr Study
Elisabeth De Greef, Dan Turner, Richard K. Russell, Anne M. Griffiths, Jarosław Kierkuś, Bartosz Korczowski, Monika Meglicka, Stanley A. Cohen, Jeffrey S. Hyams, Joel R. Rosh, Richard Strauss, Omoniyi J. Adedokun, Jose Salas, Yuhua Wang, Paul J. Ufberg, Els Van Limbergen
Safety and Efficacy of Ustekinumab in Indian Patients with Moderate to Severe Crohn’s Disease: A Multicentre, Interventional, Phase IV study
Rupa Banerjee, Vineet Ahuja, Gourdas Choudhuri, Ashok Dalal, Mukesh Kalla, Rajiv Mehta, Vandana Midha, Nitin Behl, Ravi Kant Kumar, Sagar Panchal, Nishita Shah, Utkarsha Kulkarni, Milind Rege
Safety of Guselkumab in Patients Aged ≥60 Years Old with Immune-Mediated Inflammatory Disease: A Pooled Analysis of Registrational Trials in UC, CD, PsA and PsO
Adam S. Faye, Shaji Sebastian, Victoria McCaffrey, Ivana Bravata, Maciej Nazar, Scott Newcomer, Darren Piscitelli, Shashi Adsul, Jacqueline Yee, Thomas Baker, Bruce E. Sands
Symptomatic Improvement With Intravenous Guselkumab Induction Therapy is Observed Early in Patients with Moderately to Severely Active Ulcerative Colitis: Post-hoc Analysis of QUASAR
Axel Dignass, Fumihito Hirai, Masayuki Saruta, Ayako Sasaki, Shinichi Yoshigoe, Jianmin Zhuo, Yishen Yang, Keira Herr, Tadakazu Hisamatsu
The UNITI Jr Study: Safety and Efficacy Results of Ustekinumab in Paediatric Patients with Crohn’s Disease
Dan Turner, Elisabeth De Greef, Jarosław Kierkuś, Bartosz Korczowski, Monika Meglicka, Richard K. Russell, Stanley A. Cohen, Jeffrey S. Hyams, Anne M. Griffiths, Joel R. Rosh, Richard Strauss, Els Van Limbergen, Omoniyi J. Adedokun, Lilianne Kim, Sheri Volger
Unsupervised Machine Learning to Identify Distinct Response Patterns to Guselkumab in Participants With Crohn’s Disease: Post Hoc Analysis of the GRAVITI and GALAXI 2/3 Studies
Stefan Schreiber, Geert D’Haens, Walter Reinisch, Ailsa Hart, Sudheer Rani, Mobolaji Olurinde, Rian Van Rampelbergh, Long-Long Gao, Zijiang Yang, Timothy Hoops, Chandni Valiathan, Parambir S. Dulai
Use of Intestinal Ultrasound and Other Imaging Tests in Ulcerative Colitis and Crohn’s Disease: Insights from a German Physician Survey
Irina Blumenstein, Xiaoxiao Alice Lu, Ursula Kleine-Vossbeck, Shashi Adsul, Yichen Zhang, Meshal Imran, Yan Wang, Aolin Wang, Rouven Hecht, Lukas Scharfenberger, Julian Pohlan, Ivana Bravata, Darren Piscitelli, Jessica Smith, Anyu Zhu, Claudia Ott
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.